{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:00:17Z","timestamp":1772136017345,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Michael and Amira Dan Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Meningiomas, the most common adult brain tumors, recur in up to half of cases. This requires timely intervention and therefore accurate risk assessment of recurrence is essential. Our current practice relies heavily on histological grade and extent of surgical excision to predict meningioma recurrence. However, prediction accuracy can be as poor as 50% for low or intermediate grade tumors which constitute the majority of cases. Moreover, attempts to find molecular markers to predict their recurrence have been impeded by low or heterogenous genetic signal. We therefore sought to apply systems-biology approaches to transcriptomic data to better predict meningioma recurrence. We apply gene co-expression networks to a cohort of 252 adult patients from the publicly available genetic repository Gene Expression Omnibus. Resultant gene clusters (\u201cmodules\u201d) were represented by the first principle component of their expression, and their ability to predict recurrence assessed with a logistic regression model. External validation was done using two independent samples: one merged microarray-based cohort with a total of 108 patients and one RNA-seq-based cohort with 145 patients, using the same modules. We used the bioinformatics database Enrichr to examine the gene ontology associations and driver transcription factors of each module. Using gene co-expression analysis, we were able predict tumor recurrence with high accuracy using a single module which mapped to cell cycle-related processes (AUC of 0.81\u2009\u00b1\u20090.09 and 0.77\u2009\u00b1\u20090.10 in external validation using microarray and RNA-seq data, respectively). This module remained predictive when controlling for WHO grade in all cohorts, and was associated with several cancer-associated transcription factors which may serve as novel therapeutic targets for patients with this disease. With the easy accessibility of gene panels in healthcare diagnostics, our results offer a basis for routine molecular testing in meningioma management and propose potential therapeutic targets for future research.<\/jats:p>","DOI":"10.1038\/s41598-020-74482-2","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T06:03:14Z","timestamp":1603346594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Meta-gene markers predict meningioma recurrence with high accuracy"],"prefix":"10.1038","volume":"10","author":[{"given":"Zsolt","family":"Zador","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander P.","family":"Landry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Haibe-Kains","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Cusimano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"74482_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070972","author":"M Vernooij","year":"2007","unstructured":"Vernooij, M. & Ikram, M. Incidental findings on brain MRI in the general population. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa070972 (2007).","journal-title":"N. Engl. J. Med."},{"key":"74482_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3171\/2014.7.JNS131644","volume":"122","author":"L Rogers","year":"2015","unstructured":"Rogers, L. et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J. Neurosurg. 122, 4\u201323 (2015).","journal-title":"J. Neurosurg."},{"key":"74482_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0090-3019(86)90259-4","volume":"26","author":"J J\u00e4\u00e4skel\u00e4inen","year":"1986","unstructured":"J\u00e4\u00e4skel\u00e4inen, J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg. Neurol. 26, 461\u2013469 (1986).","journal-title":"Surg. Neurol."},{"key":"74482_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3171\/jns.2001.95.4.0601","volume":"95","author":"R Ketter","year":"2001","unstructured":"Ketter, R. et al. Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J. Neurosurg. 95, 601\u2013607 (2001).","journal-title":"J. Neurosurg."},{"key":"74482_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/bpa.12110","volume":"24","author":"S Goutagny","year":"2014","unstructured":"Goutagny, S. et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 24, 184\u2013189 (2014).","journal-title":"Brain Pathol."},{"key":"74482_CR6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/neuonc\/nox018","volume":"19","author":"\u00dc Yesil\u00f6z","year":"2017","unstructured":"Yesil\u00f6z, \u00dc. et al. Frequent AKT1E17Kmutations in skull base meningiomas are associated with mTOR and ERK1\/2 activation and reduced time to tumor recurrence. Neuro Oncol. 19, 1088\u20131096 (2017).","journal-title":"Neuro Oncol."},{"key":"74482_CR7","first-page":"345","volume":"19","author":"J Boetto","year":"2017","unstructured":"Boetto, J., Bielle, F., Sanson, M., Peyre, M. & Kalamarides, M. SMO mutation status defines a distinct and frequent Molecular subgroup in olfactory groove meningiomas. Neuro Oncol. 19, 345\u2013351 (2017).","journal-title":"Neuro Oncol."},{"key":"74482_CR8","doi-asserted-by":"publisher","first-page":"21715","DOI":"10.1073\/pnas.1912858116","volume":"116","author":"AJ Patel","year":"2019","unstructured":"Patel, A. J. et al. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc. Natl. Acad. Sci. 116, 21715 (2019).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74482_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri, F. et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. 21, 901\u2013910 (2019).","journal-title":"Neuro Oncol."},{"key":"74482_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-06982-3","volume":"20","author":"A Barciszewska","year":"2020","unstructured":"Barciszewska, A. Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas. BMC Cancer 20, 1\u201313 (2020).","journal-title":"BMC Cancer"},{"key":"74482_CR11","doi-asserted-by":"publisher","first-page":"e54114","DOI":"10.1371\/journal.pone.0054114","volume":"8","author":"F Gao","year":"2013","unstructured":"Gao, F. et al. DNA methylation in the malignant transformation of meningiomas. PLoS ONE 8, e54114 (2013).","journal-title":"PLoS ONE"},{"key":"74482_CR12","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1371\/journal.pgen.0020130","volume":"2","author":"A Ghazalpour","year":"2006","unstructured":"Ghazalpour, A. et al. Integrating genetic and network analysis to characterize genes related to mouse weight. PLoS Genet. 2, 1182\u20131192 (2006).","journal-title":"PLoS Genet."},{"key":"74482_CR13","doi-asserted-by":"publisher","first-page":"17402","DOI":"10.1073\/pnas.0608396103","volume":"103","author":"S Horvath","year":"2006","unstructured":"Horvath, S. et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc. Natl. Acad. Sci. 103, 17402\u201317407 (2006).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74482_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nn.4256","volume":"19","author":"P Langfelder","year":"2016","unstructured":"Langfelder, P. et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat. Neurosci. 19, 623\u2013633 (2016).","journal-title":"Nat. Neurosci."},{"key":"74482_CR15","doi-asserted-by":"crossref","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).","DOI":"10.1186\/1471-2105-9-559"},{"key":"74482_CR16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett, T. et al. NCBI GEO: archive for functional genomics data sets\u2014update. Nucleic Acids Res. 41, 991\u2013995 (2013).","journal-title":"Nucleic Acids Res."},{"key":"74482_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1750-3639.2008.00191.x","volume":"19","author":"MD Tabernero","year":"2009","unstructured":"Tabernero, M. D. et al. Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol. 19, 409\u2013420 (2009).","journal-title":"Brain Pathol."},{"key":"74482_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1750-3639.2009.00356.x","volume":"20","author":"Y Lee","year":"2011","unstructured":"Lee, Y. et al. Genomic landscape of meningiomas. Brain Pathol. 20, 751\u2013762 (2011).","journal-title":"Brain Pathol."},{"key":"74482_CR19","doi-asserted-by":"crossref","unstructured":"Schmidt, M. et al. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget 7, 14551\u201314568 (2016).","DOI":"10.18632\/oncotarget.7396"},{"key":"74482_CR20","doi-asserted-by":"publisher","first-page":"e17238","DOI":"10.1371\/journal.pone.0017238","volume":"6","author":"C Chen","year":"2011","unstructured":"Chen, C. et al. Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods. PLoS ONE 6, e17238 (2011).","journal-title":"PLoS ONE"},{"key":"74482_CR21","doi-asserted-by":"crossref","unstructured":"Zhang, B. & Horvath, S. A general framework for weighted gene co-expression network analysis. Stat. Appl. Genet. Mol. Biol. 4, 17 (2005).","DOI":"10.2202\/1544-6115.1128"},{"key":"74482_CR22","unstructured":"Methods, T. et al. Package \u2018dynamicTreeCut\u2019. 1\u201314 (2016)."},{"key":"74482_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 128 (2013).","journal-title":"BMC Bioinform."},{"key":"74482_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, 90\u201397 (2016).","journal-title":"Nucleic Acids Res."},{"key":"74482_CR25","doi-asserted-by":"crossref","unstructured":"Robin, X. et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinform. 12, 77 (2011).","DOI":"10.1186\/1471-2105-12-77"},{"key":"74482_CR26","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing. R Found. Stat. Comput. Vienna Austria0, {ISBN} 3-900051-07-0 (2016)."},{"key":"74482_CR27","first-page":"1","volume":"7","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 overexpression in benign meningioma tissue and serum. PLoS ONE 7, 1\u201310 (2012).","journal-title":"PLoS ONE"},{"key":"74482_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-017-2457-1","volume":"133","author":"R Kikuchi","year":"2017","unstructured":"Kikuchi, R., Sampetrean, O., Saya, H. & Yoshida, K. Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. J. Neurooncol. 133, 297\u2013307 (2017).","journal-title":"J. Neurooncol."},{"key":"74482_CR29","doi-asserted-by":"publisher","first-page":"63605","DOI":"10.18632\/oncotarget.18868","volume":"8","author":"X Feng","year":"2017","unstructured":"Feng, X., Zhang, C., Zhu, L., Zhang, L. & Li, H. DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma. Oncotarget 8, 63605\u201363619 (2017).","journal-title":"Oncotarget"},{"key":"74482_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.00001","volume":"9","author":"H Zhao","year":"2019","unstructured":"Zhao, H. et al. High expression of DEPDC1 promotes malignant phenotypes of breast cancer cells and predicts poor prognosis in patients with breast cancer. Front. Oncol. 9, 1\u201311 (2019).","journal-title":"Front. Oncol."},{"key":"74482_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","volume":"20","author":"D Simpson","year":"1957","unstructured":"Simpson, D. The recurrence of intracranlal meningiomas after surgical treatment. J. Neurol. Neurosurg. Psychiatry 20, 22\u201339 (1957).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74482-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74482-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74482-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T16:37:13Z","timestamp":1670344633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74482-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74482"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74482-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/692624","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11709\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants, participation in speakers\u2019 bureaus, membership, employment, consultancies, stock ownership, or other equity interest, and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18028"}}